Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Cyber Monday streaming deals 2025: Grab the Disney+ Hulu bundle for only $5 and save over 60% - 2One spent $20 on candy. Another paid $700 for a custom costume. Here's how Halloween costs stacked up this year.
- 3Language Learning Applications for Voyagers
- 4New movies to watch this weekend: See 'We Bury the Dead' in theaters, rent 'Wicked: For Good,' stream 'The Unbreakable Boy' on Starz
- 510 Picturesque Campgrounds That Will Raise Your Outside Involvement with American
- Passover under fire: Israelis balance fatigue with cautious hope after month of war
- Weight-loss pill approval set to accelerate food industry product overhauls
- A Manual for Pick Great Lawful Discussion Administrations For New businesses In 2024
- Exclusive-Drugmakers raise US prices on 350 medicines despite pressure from Trump
- Most loved Well known Accessory Styles For 2024
- Heading to Florida for NASA's Artemis 2 moon launch? Here's what to know before you go
- Transform the daily grind to make life more interesting – a philosopher shares 3 strategies to help you attain the good life
- Will your baby get a hep B vaccine? What RFK panel's ruling means.
- 5 Home Improvement Styles: Decision in favor of Your #1
